Oxford Cannabinoid Tech.Holdings Director Dealing (7352Q)
20 Octubre 2023 - 1:04AM
UK Regulatory
TIDMOCTP
RNS Number : 7352Q
Oxford Cannabinoid Tech.Holdings
20 October 2023
Oxford Cannabinoid Technologies Holdings plc
("OCTP" or the "Company")
Director Dealing
Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the
pharmaceutical company developing prescription cannabinoid
medicines, announces that it has been informed that Kingsley
Capital Partners LLP ("KCP"), has sold 54,864,286 ordinary shares
of GBP0.01 each in the issued share capital of the Company of which
20,457,483 were acquired by Neil Mahapatra in his own name. Neil
Mahapatra, the Managing Partner of KCP, (through his beneficial
interest in up to 54.3 per cent. of KCP's shareholding in the
Company) controls the exercise of 100 per cent. of KCP's voting
rights in OCT.
The PDMR form of Neil Mahapatra is set out below.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 (which forms part of
domestic UK law pursuant to the European Union (Withdrawal) Act
2018).
The Directors of the Company accept responsibility for the
content of this announcement.
Enquiries:
O xford Cannabinoid Technologies
Holdings plc +44 (0)20 3034 2820
Clarissa Sowemimo-Coker (CEO) clarissa@oxcantech.com
Cairn Financial Advisers LLP
Emily Staples +44 (0)20 7213 0897
Jo Turner +44 (0) 20 7213 0885
Axis Capital Markets Limited
Richard Hutchison +44 (0)20 3026 0320
020 3745 0293 / 07799
Acuitas Communications 767676
Simon Nayyar simon.nayyar@acuitascomms.com
Arthur Dingemans arthur.dingemans@acuitascomms.com
About Oxford Cannabinoid Technologies Holdings Plc:
Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the
holding company of Oxford Cannabinoid Technologies Ltd (together
the "Group"), a pharmaceutical Group developing prescription
cannabinoid medicines initially targeting the U$ multi-billion
global pain market.
OCTP currently has a portfolio of four drug development
programmes. Its lead compound, OCT461201, will initially target
neuropathic and visceral pain (including irritable bowel syndrome
("IBS") and chemotherapy induced peripheral neuropathy ("CIPN"))
Dosing of all the cohorts of the Phase I, single ascending dose
study for OCT461201 has been successfully completed. No safety or
tolerability concerns were exhibited with any dose tested. As a
result, OCTP is satisfied that it is safe to proceed to the next
stage of clinical development of its lead compound. The global
market for CIPN alone is currently forecast to reach US$1.17bn by
2028.
OCTP's drug development pipeline comprises both natural and
synthetic compounds, and includes compounds targeting trigeminal
neuralgia, a severe type of face pain, and cannabinoid derivatives
targeting pain and potentially other therapeutic areas. Having
established an exclusive license agreement with Canopy Growth
Corporation for their entire pharmaceutical cannabinoid derivative
library, OCTP now has a portfolio of almost five hundred
derivatives and intellectual property rights including fourteen
patent families and associated research data.
OCTP has a clearly defined path to commercialisation, revenues
and growth. The Group is developing drug candidates through
clinical trials to gain regulatory approval (FDA/MHRA/EMA) that
will enable medical professionals to prescribe them with
confidence. OCTP's portfolio aims to balance risk, value and time
to market, whilst ensuring market exclusivity around all its key
activities.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
a. Name Indraneil Mahapatra
2 Reason for notification
a. Position/Status NED of Oxford Cannabinoid Technologies Holdings
PLC ("OCT")
b. Initial notification/ Initial notification
Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Oxford Cannabinoid Technologies Holdings
plc
b. LEI 2138005SRWT4998BCE35
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a. Description of Oxford Cannabinoid Technologies Holdings
the financial PLC
instrument, type Ordinary shares of GBP0.01 each
of instrument GB00BMVMRB86
Identification
Code
b. Nature of the Prior to the transaction, being the subject
transaction of this disclosures. Kingsley Capital Partners
LLP ("KCP") held 198,466,493 ordinary shares
of GBP0.01 each in the issued share capital
of OCT ("Ordinary Shares"). Indraneil Mahapatra,
the Managing Partner of KCP, (through his
beneficial interest in up to 54.3 per cent.
of KCP's shareholding in the Company) controls
the exercise of 100 per cent. of KCP's voting
rights in OCT. Therefore, prior to this
disclosure the holding of Indraneil Mahapatra
in OCT comprised a total of 199,355,382
Ordinary Shares, being 198,466,493 Ordinary
Shares held by KCP and 888,889 Ordinary
Shares held by Rachel Matharu (Neil Mahapatra's
wife).
KCP has now reduced its holding in Ordinary
Shares by 54,864,286 Ordinary Shares of
which 20,457,483 Ordinary Shares were acquired
by Indraneil Mahapatra in his own name.
The resulting position is as follows:
(a) KCP holds 143,602,208 Ordinary Shares
of which Indraneil Mahapatra retains 100%
of the voting rights; and
(b) Indraneil Mahapatra holds 20,457,483
Ordinary Shares in his own name and 888,889
Ordinary Shares held by Rachel Matharu (Indraneil
Mahapatra's wife).
Indraneil Mahaptra therefore has voting
rights over a total of 164,948,580 Ordinary
Shares which represents approximately 17.17%
of the issued share capital of OCT.
c. Price(s) and volume(s) Price(s) Volume(s)
GBP0.0081 54,864,286
(KCP disposal)
GBP0.0081 20,457,483
(Indraneil
Mahapatra acquisition)
d. Aggregated information -- Disposal of 54,864,286 Ordinary Shares
by KCP @ GBP0.0081 per Ordinary Share
- Aggregated Volume -- Acquisition of 20,457,483 Ordinary Shares
by Neil Mahapatra @ GBP0.0081 per share
- Price
e. Date of the transaction 18(th) October 2023
f. Place of the transaction London
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFVTIALALIV
(END) Dow Jones Newswires
October 20, 2023 02:04 ET (06:04 GMT)
Oxford Cannabinoid Techn... (LSE:OCTP)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Oxford Cannabinoid Techn... (LSE:OCTP)
Gráfica de Acción Histórica
De May 2023 a May 2024
